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BACKGROUND: Infertility is an important side effect of treatments used for cancer and other non-malignant conditions in males. This
may be due to the loss of spermatogonial stem cells (SSCs) and/or altered functionality of testicular somatic cells (e.g. Sertoli cells, Leydig
cells). Whereas sperm cryopreservation is the first-line procedure to preserve fertility in post-pubertal males, this option does not exist for
prepubertal boys. For patients unable to produce sperm and at high risk of losing their fertility, testicular tissue freezing is now proposed as an
alternative experimental option to safeguard their fertility.
OBJECTIVE AND RATIONALE: With this review, we aim to provide an update on clinical practices and experimental methods, as well as
to describe patient management inclusion strategies used to preserve and restore the fertility of prepubertal boys at high risk of fertility loss.
SEARCH METHODS: Based on the expertise of the participating centres and a literature search of the progress in clinical practices, patient
management strategies and experimental methods used to preserve and restore the fertility of prepubertal boys at high risk of fertility loss
were identified. In addition, a survey was conducted amongst European and North American centres/networks that have published papers on
their testicular tissue banking activity.
OUTCOMES: Since the first publication on murine SSC transplantation in 1994, remarkable progress has been made towards clinical
application: cryopreservation protocols for testicular tissue have been developed in animal models and are now offered to patients in clinics as
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are being evaluated in mouse and primate models. However, important practical, medical and ethical issues must be resolved before fertility
restoration can be applied in the clinic.
Since the previous survey conducted in 2012, the implementation of testicular tissue cryopreservation as a means to preserve the fertility of
prepubertal boys has increased. Data have been collected from 24 co-ordinating centres worldwide, which are actively offering testis tissue
cryobanking to safeguard the future fertility of boys. More than 1033 young patients (age range 3 months to 18 years) have already undergone
testicular tissue retrieval and storage for fertility preservation.
LIMITATIONS, REASONS FOR CAUTION: The review does not include the data of all reproductive centres worldwide. Other centres
might be offering testicular tissue cryopreservation. Therefore, the numbers might be not representative for the entire field in reproductive
medicine and biology worldwide. The key ethical issue regarding fertility preservation in prepubertal boys remains the experimental nature of
the intervention.
WIDER IMPLICATIONS: The revised procedures can be implemented by the multi-disciplinary teams offering and/or developing treatment
strategies to preserve the fertility of prepubertal boys who have a high risk of fertility loss.
STUDY FUNDING/COMPETING INTEREST(S): The work was funded by ESHRE. None of the authors has a conflict of interest.
Key words: cryopreservation / in vitro spermatogenesis / fertility preservation / fertility restoration / prepubertal boys / spermatogonial
stem cell / testicular tissue freezing / testis / transplantation
WHAT DOES THIS MEAN FOR PATIENTS?
Future fertility is important for long-term quality of life in patients who have received chemotherapy and/or radiotherapy during childhood.
New strategies to give patients hope of fathering their own child must therefore be developed and brought into clinical practice. Testicular
tissue cryopreservation is currently the only possibility to preserve fertility potential in children because sperm are not produced until
puberty.
Methods to obtain mature sperm from prepubertal testicular tissue are under investigation and studies in monkeys have shown the feasibility.
Hence, an increasing number of centres worldwide now advocate testicular tissue cryobanking as an experimental approach for patients with
the objective of obtaining mature sperm from the tissue in the future. Approaches under investigation include in vitro culture or autologous
transplantation of testicular tissue or cells. This review will describe current progress in fertility preservation for prepubertal boys, while also
describing the challenges that must be overcome before these approaches can be implemented in clinical practice.
Introduction
Male gonads contain spermatogonial stem cells (SSCs), which are
at the foundation of spermatogenesis that gives rise to mature and
fertilization-competent spermatozoa. Sperm production begins at
puberty and continues throughout adulthood. Germ cell loss can
be induced by cytotoxic treatments, but is also linked to hereditary
conditions such as Klinefelter syndrome or Fanconi syndrome. There-
fore, to prevent infertility in disorders or conditions associated with
prepubertal germ cell loss, well-timed cryopreservation of testicular
tissues containing SSCs is a promising experimental strategy. Various
approaches for the restoration of male fertility following oncological
treatments or other fertility-compromising diseases are now under
investigation. These approaches include SSC transplantation, testicular
tissue grafting and in vitro spermatogenesis.
Worldwide, an increasing number of institutions are offering fertility
preservation to prepubertal boys facing SSC loss. The first fertility
preservation programme for prepubertal males started in 2002, and
the number of centres offering cryopreservation has steadily increased
over recent years (Picton et al., 2015). We anticipate that, in the near
future, patients will return with questions regarding clinical options
to restore their fertility. Therefore, the present review will describe
current clinical practices, patient inclusion strategies and experimental
methods used to preserve and restore the fertility of prepubertal
boys at high risk of fertility loss. In addition, the scientific, ethical and




























































Impact of irradiation and cytotoxic
treatments on testicular function
Testicular cells, especially rapidly dividing germ cells, are highly sensitive
to irradiation and chemotherapy treatment. The potential for recovery
will depend on survival of spermatogonial populations within the
testis. Low cytotoxic doses will deplete the pool of differentiating
spermatogonia but are likely to result in only temporary cessation of
spermatogenesis, while reserve SSCs may survive and resume mitotic
activity to produce differentiating spermatogonia. If the damage is
severe and the SSC number is drastically reduced, recovery may not
occur until many years later. If all SSCs are depleted, the patient
becomes permanently infertile. Spermatogonia have been shown to
be susceptible to such depletion at all stages of life, including child-
hood (Whitehead et al., 1982; Relander et al., 2000; Jahnukainen et
al., 2011). Furthermore, patient age, preexisting testicular pathology
and the individual susceptibility to cancer treatment toxicity may also
influence the potential of the seminiferous epithelium to support
spermatogenesis after treatment (Wyns et al., 2010; Rives et al.,
2012).
In a systematic literature review, the International Late Effects of
Childhood Cancer Guideline Harmonization Group found evidence
for adverse effects of cyclophosphamide, mechlorethamine and
procarbazine on spermatogenesis (Skinner et al., 2017). Alkylating
agent–based hematopoietic stem cell transplant (HSCT) condition-
ing regimens (i.e. busulfan and cyclophosphamide, fludarabine or
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spermatogenesis. Data have suggested a relationship between
the dose of alkylating agents and the likelihood of developing
impaired spermatogenesis (Skinner et al., 2017). Azoospermia and
oligozoospermia are unlikely after cyclophosphamide equivalent doses
<4000 mg/m2 (Green et al., 2014). However, a threshold dose that
predicts impaired spermatogenesis, azoospermia or any completely
safe lower threshold dose could not be identified (Green et al.,
2014; Skinner et al., 2017). Alkylating agents used in combination
are considered to have an additive adverse effect on spermatogenesis
(Skinner et al., 2017).
Assessing spermatogonial quantity per tubular cross section
(Masliukaite et al., 2016) offers a method to measure adverse effects of
disease or its therapy on quality and fertility potential of tissue obtained
from prepubertal boys (Poganitsch-Korhonen et al., 2017; Stukenborg
et al., 2018a). Using this approach, it has been shown that patients
exposed to alkylating agents, especially to cyclophosphamide equiva-
lent doses >4000 mg/m2, show significantly reduced spermatogonial
quantity compared to normative reference values or those for patients
treated with non-alkylating agents (Poganitsch-Korhonen et al., 2017).
Therefore, in order to collect sufficient amounts of spermatogonia
for fertility preservation, a testicular biopsy sample should be acquired
early, before the initiation of alkylating agent chemotherapy.
Testicular irradiation can impair spermatogenesis by directly
damaging germ cells, spermatogenesis-supporting Sertoli cells and
testosterone-producing Leydig cells (Kenney et al., 2012; Stukenborg
et al., 2018b). The differentiating spermatogonia are radiosensitive to
scattered doses as low as 0.1 Gy leading to short-term cessation of
spermatogenesis (Rowley et al., 1974). Doses of 2–3 Gy also affect
SSCs and cause long-term azoospermia. Doses in excess of 6 Gy
are able to deplete the SSC pool and lead to permanent infertility
(Rowley et al., 1974; Centola et al., 1994). It is also well established
that even very small doses invariably cause acute impairment and
that recovery does not always occur. Thus, any dose of testicular
radiotherapy should be regarded as possibly increasing the risk of
impaired spermatogenesis (Skinner et al., 2017). Pubertal status in
humans at the time of HSCT has been shown to be an independent
predictor of adult testicular volume (Wilhelmsson et al., 2014),
which in turn is primarily determined by Sertoli cell number (Sharpe
et al., 2003). Total body irradiation (TBI 10–12 Gy) used to prepare
a patient for HSCT before initiation of pubertal maturation leads to
significantly smaller adult testicular volumes compared to same therapy
during or after puberty (Wilhelmsson et al., 2014). These findings
provide evidence for effects of cancer treatments also on the Sertoli
cell population. There are several studies suggesting that testicular
radiotherapy doses ≥21–24 Gy and the majority of those ≥12 Gy,
including TBI are probably associated with an increased risk of Leydig
cell failure resulting in testosterone deficiency (Skinner et al., 2017).
Chemotherapy-induced Leydig cell failure is instead relatively rare
(Sklar, 1999).
Which patients are at risk for fertility loss?
Crucial for a successful fertility preservation practice is the selection of
patients who will benefit from this service. Since the surgical removal
of testicular tissue is an invasive procedure and fertility restoration
strategies from those tissues are still at an experimental level, the





























































































































restricted to patients at significant risk of treatment-induced testicular
damage and subsequent infertility. The inclusion criteria for testicular
tissue cryobanking in prepubertal and adolescent male patients differ
between centres (Wyns et al., 2011; Picton et al., 2015). In some
centres, testicular tissue banking is restricted to patients who have not
received any previous treatment (Wyns et al., 2011). Other centres
also include patients that already have had a previous round of chemo-
or radiotherapy (Stukenborg et al., 2018a; Valli-Pulaski et al., 2019;
Braye et al., 2019). Most testicular tissue banking is performed in
prepubertal boys suffering from cancer and mainly before treatment
of testicular cancer, Hodgkin’s and non-Hodgkin’s malignant lymphoma
and solid tumours (Picton et al., 2015).
Testicular tissue cryopreservation has been offered to patients at sig-
nificant risk of infertility as a result of a treatment that is planned or has
recently been initiated and patients at risk of genetically predisposed
testicular degeneration.
Patients receiving therapies associated with a high risk of infertility
include those receiving allogeneic or autologous HSCT or irradiation
exposure to the testes, while first-line chemotherapy with antimetabo-
lites, vinca alkaloids, podophyllotoxins and antitumor antibiotics are
associated with a low risk of infertility (Skinner et al., 2017). There-
fore, the majority of childhood cancer patients do not meet the
criteria of a significant risk of impaired fertility at the time of cancer
diagnosis; however, poor disease response or relapse may result in
reclassification of patients into treatment regimens that often involve
potentially sterilising therapy (Jahnukainen et al., 2015). This means
that many cancer patients at the time of fertility preservation have
already received chemotherapy, which may decrease the quality of
cryopreserved tissue. On the other hand, if only untreated patients
are eligible for fertility preservation, this may improve the quality
of cryopreserved tissue but would mean that testicular biopsy is
offered to a large patient population (if not restricted to the high-
risk group), many of whom might not become infertile. Furthermore,
this would also mean that relapsed patients would not qualify for tes-
ticular tissue cryopreservation, even for those whose SSC population
might not be affected by the previous treatment. Therefore, patients
treated with non-alkylating agents having a SSC population in the nor-
mal range according to published reference values (Masliukaite et al.,
2016) should with relapse get the possibility for fertility preservation
after this first treatment (Poganitsch-Korhonen et al., 2017; Stukenborg
et al., 2018a). However, the quality of the germ cells cryopreserved
during or shortly after chemotherapy could be theoretically affected
and further studies are needed to elucidate the potential impairments
in detail.
Allogeneic HSCT is a curative treatment option for patients with
bone marrow failure, thalassemia, sickle cell disease and many other
genetic diseases. As a consequence, there are an increasing number
of children with non-malignant conditions at risk of potential loss of
fertility. While early studies document spontaneous puberty among
children receiving reduced-intensity conditioning (Panasiuk et al., 2015),
limited data are currently available on fertility effects. These studies
demonstrate a 50% risk of azoospermia after HSCT or long-term
treatment with hydroxyurea for sickle cell disease (Lukusa et al., 2009).
Therefore, testicular tissue preservation is also indicated in this patient
group.
As spermatogonial quantity is also reduced in non-malignant diseases
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and immunodeficiency caused by a variant of the forkhead box P3
(FOXP3) gene) (Stukenborg et al., 2018a), the primary disease may
also impact gonadal function or increase susceptibility to the toxicity of
subsequent therapy. In light of this evidence, more research is needed
to understand treatment- and patient-related factors that may impact
on fertility preservation practice. This will allow for optimization of
patient selection and timing of testicular biopsy.
Individuals with Klinefelter syndrome face germ cell depletion during
development and, hence, azoospermia in >90% cases (Franik et al.,
2016; Van Saen et al., 2018). Cryopreservation of testicular biopsies
from adolescent Klinefelter syndrome patients is performed as part
of the fertility preservation programme in some centres (Heckmann
et al., 2018; Rives et al., 2018; Van Saen et al., 2018). However, as
SSCs are lost at a very early age (<4 years), the question of whether
fertility preservation should be offered to prepubertal patients with





Management of fertility preservation
Lack of time in the case of cancer patients and lack of care-provider
knowledge on infertility risk have been identified as the main barriers
to including fertility preservation in patient care. Therefore, proper
and efficient management in the field requires a team of highly trained
physicians, nurses and psychologists (Fig. 1). Ideally, those teams are
involved in both oncology and reproductive medicine in order to con-
sider the challenges of each diagnosis and patient. Multi-collaborative
care pathways (MCCPs), including well-informed care providers, with
enhanced communication between oncologists and reproductive spe-
cialists, facilitate shared decisions at the time of diagnosis and lead
to increased patient referrals and acceptance rates of the procedure
(Wyns et al., 2015). In the male paediatric population, the highest
acceptance rates were achieved with face-to-face consultations at the
time of cancer diagnosis in a small pilot study (Ginsberg et al., 2010),
which was further confirmed in a larger series of patients suffering from
benign and malignant haematological diseases (74% for boys under
12 years) (Wyns et al., 2015). Such MCCPs should support the treating
oncologists in order to facilitate the timely implementation of fertility
preservation measures and offer appropriate nurse support and pae-
diatric psychology counselling to enhance patient and parent support
at the time of diagnosis. It is therefore of paramount importance
to identify and educate key staff capable of initiating discussions on
fertility and fertility preservation strategies and provide clear referral
pathways to facilitate fertility-related discussions in paediatric oncology
(Armuand et al., 2017). Dialogue with patients and parents was also
shown to be critical for informed decision-making (Nagel and Neal,
2008; Carlson et al., 2017). Discussions should not only aim to provide
full and understandable information of experimental strategies but also
place the emphasis on the future hope for parenthood as a positive
decisional factor. However, parents and patients must be informed
about the experimental nature of the procedures. Furthermore, access





























































































































process (Vadaparampil et al., 2008). Patient information and decision
aids should be age-adapted and should be available in multilingual
versions (Rodriguez-Wallberg et al., 2019).
Adequate management should be tailored to the individual patient.
Hence, besides constraints directly linked to disease-specific care,
it is essential that care providers have detailed knowledge of the
hormonal events and testicular physiology before and around puberty.
This is required in order to provide patients/parents with accurate
information regarding the options for cryopreservation of gametes
or gonadal tissue. This is especially the case for peripubertal boys as
haploid germ cells and/or mature sperm may be present in the testis
of these boys (even in the absence of ejaculated sperm) (Wyns et al.,
2011). Considering that protocols used to preserve mature germ cells
differ from those used to preserve testicular tissue containing SSCs,
institutional guidelines aimed at prioritising cryobanking of testicular
sperm whenever possible rather than testicular tissue should be avail-
able (Picton et al., 2015).
Patients requiring gonadotoxic therapies should be referred to a
fertility specialist before gonadotoxic treatment is initiated (Redig et al.,
2011). However, real-life clinical care showed that a proportion of
patients and/or their parents or guardians requested fertility preser-
vation measures while chemotherapy was already in its early phase
(Abofoul-Azab et al., 2018). Moreover, as oncological therapy remains
a health priority, fertility preservation should be considered and dis-
cussed where possible.
To develop further guidance in the field of fertility preservation,
integration of the patients that participated in fertility preservation
programmes into a systematic long-term follow-up (Melan et al., 2018)
is recommended. It is important to inform the patients and their
parents that, to date, the possible future use of frozen testicular tissue
remains a research activity.
Besides hospital-wide MCCPs, establishment of structured networks
between clinics is an important step for an optimal management of
fertility preservation given that inequalities in access exist. Although
oncological therapies should take priority over fertility preservation
strategies, fertility and its preservation should always be discussed and
considered where possible.
Procedure of fertility preservation
In peripubertal boys, it is theoretically possible to freeze sperma-
tozoa obtained after sperm collection performed by masturbation.
However, in case of failure or refusal of sperm collection, severe
oligozoospermia, azoospermia or necrozoospermia (Safsaf et al., 2011;
Daudin et al., 2015), an alternative procedure is to consider testicular
biopsy combined with testicular sperm extraction (TESE) and possibly
sperm freezing. If during surgery no sperm are retrieved, TESE can
be combined with testicular tissue freezing in order to be able to
store SSCs. As sperm production also stops for long periods after
initiation of cancer therapy (Schrader et al., 2001), it is recommended
to cryopreserve sperm before starting gonadotoxic treatment, also
to avoid chemo- and radiotherapy-induced mutagenic effect(s) on the
germ cell nucleus and the potential risk on the conceptus (miscarriages,
malformations, genetic or chromosomal anomalies) if used in ART
(Foresta et al., 2000; Picton et al., 2015). The stored spermatozoa
will be usable for IUI or IVF (conventional or with ICSI) depending on






/hropen/article-abstract/2020/3/hoaa016/5848713 by guest on 09 June 2020
An update on fertility preservation in boys 5
Figure 1 Schematic overview of a multi-collaborative care pathway for fertility preservation in boys.
In prepubertal boys who do not produce spermatozoa or in peripu-
bertal boys who have already started treatment (chemotherapy or
radiotherapy) with low gonadotoxic doses and did not have the oppor-
tunity to bank sperm beforehand, testicular tissue freezing with the
objective of preserving SSCs appears to be an acceptable solution
(Picton et al., 2015). Testicular tissue biopsy before freezing is prefer-
ably unilateral and is performed surgically according to local proce-
dures. The testicular fragments are immediately placed into a transport
medium kept at 4 to 8◦C and transported rapidly to the laboratory to
minimize the risk of hot ischemia and to minimise microbial contam-
ination. For longer distances between surgery room and laboratory,
testicular tissue can be transported at 4◦C in specialised medium
(DMEM/F12) for up to 3 days (Faes and Goossens, 2016, 2017).
The freezing of either testicular cell suspensions or testicular tissue
has been proposed to cryopreserve SSCs. However, cryopreservation
of testicular tissue pieces preserves the opportunity to pursue either
cell- or tissue-based therapies in the future. Each piece of testicular
tissue is cut into small fragments, which are deposited in cryotubes
containing a cryoprotective medium (Rives et al., 2013). At present, no
standardised protocol has been established for human testicular tissue
freezing in terms of optimal cryopreservation technique or fertility
restoration procedure able to generate spermatozoa. However, the
most commonly used freezing protocol is controlled slow freezing with
seeding (Keros et al., 2005; Keros et al., 2007; Wyns et al., 2007; Curaba
et al., 2011; Babayev et al., 2013; Poels et al., 2013; Ginsberg et al.,
2014; Pietzak 3rd et al., 2015; Ho et al., 2017; Valli-Pulaski et al., 2019).
Dimethylsulfoxide, a penetrating cryoprotective agent, has been shown
to be superior to 1,2-propanediol and glycerol in terms of cell viability
(Keros et al., 2005) and is currently used in the majority of slow freezing
protocols (Keros et al., 2007, Wyns et al., 2007, Wyns et al., 2008,




































































2013, Poels et al., 2013, Ginsberg et al., 2014, Pietzak et al., 2015, Ho
et al., 2017). Sucrose, a non-penetrating cryoprotective agent, is also
added as a component of freezing media (Wyns et al., 2007; Wyns
et al., 2008; Curaba et al., 2011; Wyns et al., 2011; Babayev et al., 2013;
Baert et al., 2013; Poels et al., 2013; Ginsberg et al., 2014; Ho et al.,
2017). Finally, some studies have explored vitrification (i.e. ultra-rapid
freezing) of testicular tissue in a small number of patients although with
no proven superiority in relation to tissue and cell integrity (Curaba et
al., 2011; Baert et al., 2013; Poels et al., 2013).
Follow-Up of Patients Offered
Testicular Tissue
Cryopreservation
Follow-up of patients offered testicular cryopreservation serves sev-
eral purposes: to determine the short- and long-term complications
of testicular biopsy in this patient group; to determine the effect
of potentially gonadotoxic treatments on subsequent reproductive
function and fertility; to adapt selection criteria for future patients by
ongoing stratification of fertility risks based on underlying diagnoses
and treatments received; and to inform patients and their families about
developments in the field that may allow them to use their tissue in the
future.
Complications associated with testicular
biopsy
Obtaining a testicular biopsy can be considered a relatively low-risk
procedure. The frequency and number of anaesthetics can be min-
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such as placement of a central venous catheter, bone marrow aspirate
or diagnostic lumbar puncture (Anderson et al., 2015). However, for
specific patient groups in whom fertility preservation is offered, there
may be potential complications that relate to their underlying disease or
treatment. For patients receiving chemotherapy and radiotherapy, or
those with conditions associated with bone marrow suppression (e.g.
aplastic anaemia), there may be additional risks of bleeding and infec-
tion. These risks can be managed by identifying thrombocytopenia and
neutropenia, and use of platelet transfusions to cover the procedure
where indicated. Careful monitoring of the wound and clinical condi-
tion of the patient in the immediate days post-surgery is also required
with prompt initiation of antibiotic treatment in the case of infection.
A limited number of studies have reported the rate of intra-operative
and short-term post-operative complications following testicular
biopsy for the purposes of fertility preservation. To date, the overall
complication rate is around 2–3% (Ginsberg et al., 2014; Ho et al.,
2017; Uijldert et al., 2017; Ming et al., 2018; Valli-Pulaski et al., 2019).
Reported complications include infection of the testicle or surgical
wound, including one reported case of wound dehiscence. Pain is
an important complication of testicular biopsy and should be regularly
assessed in the post-operative period and appropriate analgesia should
be administered. While current data suggest that testicular biopsy
for the purposes of fertility preservation is a low-risk procedure,
additional data on post-operative complications and development
of standardised guidelines for the pre-, peri- and post-operative
management of patients should be a subject for further research.
While obtaining testicular tissue for fertility preservation is the
primary goal of testicular biopsy, it is imperative that the procedure
itself does not further compromise testicular function in these patients.
Follow-up of testicular function through childhood, puberty and into
adulthood is an important aspect of current research. To date, only
one study has reported the effects of testicular biopsy over the medium
term (Uijldert et al., 2017): this prospective study in 64 boys involved
ultrasound scans to determine the volume of the biopsied testis and
comparison with the contralateral non-biopsied testis. Despite an initial
bilateral reduction in testicular volume immediately following surgery,
no differences were subsequently observed between biopsied and
non-biopsied testes at 6 and 12 months of follow-up, albeit that there
was evidence of fibrosis in the biopsied testes in a small proportion
(∼6%) of patients after 12 months of follow-up (Uijldert et al., 2017).
Importantly, the testicular volumes in these patients remained in the
prepubertal (<4 ml) range. Given that testicular volume does not
markedly increase until puberty, further studies are required to deter-
mine the long-term effect of testicular biopsy on pubertal testicular
growth and adult testicular volume in this patient group. This assess-
ment should also take the combined effect of biopsy and gonadotoxic
therapies into account.
Reproductive function in patients following
testicular tissue biopsy for cryopreservation
For individual patients, follow-up is required to ensure that puberty is
initiated and progresses normally. This is important for the assessment
of the development of secondary sexual characteristics, maintenance
of testosterone production into adulthood and fertility. Puberty can
be assessed clinically by Tanner staging and measurement of testicular





























































































































of age in at-risk individuals (Skinner et al., 2017). LH-stimulated testos-
terone production is required for development of secondary sexual
characteristics at puberty and the support of spermatogenesis in
adulthood. While LH and testosterone production at puberty and into
adulthood is usually unaffected in patients who have received cancer
treatment in childhood, fertility may still be affected as a result of
primary gonadal damage (reviewed in Stukenborg et al., 2018b). A
raised serum FSH is indicative of Sertoli cell dysfunction and impaired
spermatogenesis (Kelsey et al., 2017). Fertility potential can also be
assessed post-puberty by measurement of testicular volume, serum
gonadotrophins or by semen analysis (Skinner et al., 2017).
Adaptation of patient selection criteria for
testicular tissue cryopreservation
A key aspect of follow-up is to validate and, if necessary, adapt patient
selection criteria for testicular tissue cryopreservation. This is required
to prevent unnecessary surgery in those who subsequently retain
natural fertility, while ensuring that those who may benefit are offered
the procedure. This approach has already been successfully applied
to ovarian tissue cryopreservation, demonstrating that the current
selection criteria are able to identify those at risk of premature ovarian
failure (POF) with a high degree of accuracy (Wallace et al., 2014). In
this study, POF occurred in 30% of those who were offered ovarian
cryopreservation, while POF did not occur in the patients who were
not offered fertility preservation.
A similar approach for males would require a serial follow-up of
gonadotrophins and semen analysis, and a comparison between those
who were offered testicular biopsy and those who were not. However,
follow-up in these patients, particularly those who were not considered
for fertility preservation, may be challenging.
Recommendations for follow-up in patients
offered testicular tissue cryopreservation
Based on the current data and requirements for additional research,
prepubertal patients receiving potentially gonadotoxic treatments
should receive regular assessment of reproductive function by a
paediatric endocrinologist, andrologist or urologist. Assessment of
reproductive function should include pubertal staging, assessment of
testicular volume (using an orchidometer or ultrasound) and, where
relevant, serum gonadotrophins. Assessment of baseline Sertoli cell
function (anti-Müllerian hormone, inhibin B) may also be considered.
A pragmatic approach to post-treatment follow-up during prepuberty
may consist of infrequent (every 1–2 years) assessment of testicular
volume and gonadotrophins. From the age of 12 years, patients
should be assessed (at least annually) for pubertal status including
Tanner staging and testicular volume (Skinner et al., 2017). Assessment
and measurement of gonadotrophins and testosterone may also
be performed as part of regular pubertal assessment in order to
ensure that treatment for delayed puberty is initiated when indicated.
Pubertal delay may result from hypergonadotrophic hypogonadism
(high gonadotrophins and low testicular volumes), indicating primary
gonadal failure. Alternatively, puberty may be delayed as a result of
hypogonadotrophic hypogonadism, indicating a central cause. In boys
with delayed puberty (testicular volumes <3 ml at 14 years), pubertal
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development of secondary sexual characteristics in line with their
peers. Assessment of fertility in adulthood includes measurement of
testicular volume, serum gonadotrophin and testosterone levels and
semen analysis (Skinner et al., 2017).




A first survey of the European and Israeli centres offering cryop-
reservation of immature testicular tissues was performed in 2012
(Picton et al., 2015). In this survey, results from seven centres were
taken into account. In order to determine recent developments in the
field of male fertility preservation, the survey was repeated using an
extended questionnaire prepared by the special interest groups (SIG)
Andrology and SIG Fertility Preservation of ESHRE. The questionnaire
was sent in total to 22 contact persons from Europe and the USA,
and responses were received from 17. Survey data contain information
from 24 sites (of which some are part of a network) offering a fertility
preservation programme to cryopreserve immature testicular tissues.
Four of the remaining five contact persons stated that they were indeed
involved in collection of samples for cryopreservation, but that their
data were reported by a co-ordinating centre, and one person was
no longer situated at a clinic offering cryopreservation of testicular
tissues.
The 24 sites are located in Europe (Scandinavia, Iceland, the UK,
Belgium, the Netherlands, France, Spain, Germany), USA, Israel and
Jordan. It is of note that some co-ordinating centres offer cryopreser-
vation of immature testicular tissues to a number of collaborating
clinics in the frame of national or even international networks: in
the frame of the Nordfertil network, testicular tissues are obtained
in clinics located in Finland as well as Iceland and Sweden and are
then centrally stored at the University Hospital in Helsinki and at
Karolinska Institutet and Karolinska University Hospital, respectively.
The network in the UK stores samples in Edinburgh and Oxford, while
research is currently conducted in Edinburgh using shared samples. The
German Androprotect Network currently comprises three German
clinics as tissue retrieval sites and the University Clinic Münster as
a central location for storage of cryopreserved samples. Finally, as
recently published (Valli-Pulaski et al., 2019), the North American
network consisting of 11 international sites has centralised the cry-
opreservation of samples at the University of Pittsburgh School of
Medicine.
Impressively, while the absolute number of cryopreserved tissues
was around 260 at the time of the last survey in 2012, the total number
was 1033 in this 2019 survey, constituting a 4-fold increase (Table I).
This number adds to the recently estimated total of 700 testicular
samples stored worldwide (Valli-Pulaski et al., 2019) and demonstrates
the increasing efforts and acceptability for fertility preservation strate-
gies in boys. This development is also reflected by the fact that the
healthcare systems at least partially bear the costs for collection and
storage of the tissues in at least half of the co-ordinating centres.
This appears to be a rather recent development, as according to the
survey from 2012 (Picton et al., 2015) costs were still covered by





























































































































centre). An overview of the results from the questionnaire from 2019
is provided in Table I.
In line with the previous survey, the age of patients undergoing
testicular biopsy for preservation of spermatogonia ranged from a
few months to 18 years of age. Interestingly, the number of samples
currently stored is almost identical to the number of patients who
underwent testicular tissue retrieval. Considering that those samples
have not yet been used for the purpose of fertility restoration, these
numbers indicate that few samples have been discarded. One potential
reason for discarding a sample is the death of a patient. While some
sites allow for the use of these samples for research, samples have
to be discarded after a death at other sites. However, with informed
consent from patients or parents the tissue can be donated for research
studies.
An obvious change over the past 7 years is the composition of
the patient groups seeking fertility preservation. While in 2012 the
majority of centres had stored tissues from patients prior to onco-
logical treatments, only four centres had cryopreserved tissues from
patients with non-malignant diseases facing the risk of germ cell loss
(Picton et al., 2015). In 2019, all co-ordinating sites stated that they also
recruit patients with non-malignant disease. It is also of note that the
proportion of tissues from patients with non-malignant diseases ranges
from 2 to 91%, while this patient group makes up ≥50% or more in four
cryopreservation sites already.
In line with this development, the list of diseases mentioned as
indications for testicular tissue banking in boys has become more
diverse, in particular for the non-malignant diseases (Fig. 2A–C).
Taking 1015 of the 1033 reported testicular biopsies into account
for which clinical information was provided, patients were generally
categorised as having malignant diseases (n = 630), non-malignant dis-
eases (n = 280) and non-haematological genetic abnormalities (includ-
ing gonadal dysgenesis syndromes and disorders of sex development;
n = 105). Within these three subcategories, the most prominent dis-
eases were further classified. Among the malignant disorders, diagnosis
of haematological disorders and tumours of the central nervous system
were the most common diseases, whereas sickle cell disease and
Klinefelter syndrome were the most common indications for fertility
preservation among the non-malignant and genetic diseases, respec-
tively (Fig. 2A–C).
The questionnaire also inquired about the legal restrictions concern-
ing the cryopreserved testicular tissues, which are regulated in the
informed consent forms. While most sites do not have any specific
restrictions regarding the maximum storage time, individual sites do
require annual systematic contact with the patient’s parents or the
patient once he has turned 18 years of age. None of the sites has
reported a minimum age for fertility preservation measures.
Finally, all sites stated that the gonadal tissues are considered to be
tissues and not gametes, which has implications with regard to the legal
regulations, including reimbursement and storage costs.
Fertility Restoration: Future
Options
Although fertility preservation programmes for prepubertal boys are in
place in several medical centres around the world, methods to restore
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Table I Results based on the questionnaire prepared by the Andrology and Fertility Preservation special interest groups
of ESHRE.







(i) How many immature patients underwent
testicular tissue retrieval as a strategy for
fertility preservation?
1033
(ii) How many samples are currently stored? 989
(iii) What was the age range of pre-pubertal
patients?
3 months −18 years
(iv) Do you also recruit non-malignant
patients?
Yes (all)
(v) What is the proportion of malignant
cases?
2–98%
(vi) Which cryopreservation protocol was
applied?
Slow freezing (all)
(vii) Which cryoprotectant was used? DMSO (5)
DMSO and sucrose (1)
DMSO & HSA (3)/or patient serum &
sucrose (2)
DMSO & ethylene glycol (1)
PBS & ethylene glycol, HSA & sucrose
(1)
(viii) Who pays for collection of tissue? Health insurance (3)
Combination of health insurance and
charitable funds/grants/institution (3)
Study (1)
Study plus charitable donation (1)
The hospital (3)
(xiv) Who pays for storage? Healthcare (4)
Healthcare plus charitable funds (1)
Study plus the patient (after 1 year of
storage) (1)
Study plus charitable donation (1)
The hospital/institutional money (4)
DMSO = dimethyl sulfoxide; HSA = human serum albumin.
Numbers between brackets show the number of times this answer was given.
Currently, research is focused on three approaches: SSC propagation
and auto-transplantation, testicular tissue auto-grafting and in vitro
spermatogenesis.
SSC propagation and auto-transplantation
In vitro propagation of SSCs followed by auto-transplantation into the
seminiferous tubules via the rete testis is considered the only method
for restoration of fertility with the potential to father a child via natural
conception. In short, the proposed future clinical cell therapy will
consist of isolation of testicular cells from the cryopreserved testicular
biopsy to propagate the SSC subpopulation in vitro. Subsequently,
these propagated SSCs will be auto-transplanted into the testis of the
childhood cancer survivor who was rendered infertile due to previous
treatment(s). After transplantation, the SSCs will colonize the testis,
undergo spermatogenesis and provide continuous sperm production
allowing natural conception to occur (Brinster, 2007). This concept








































successful in 1994 in a mouse model (Brinster and Zimmermann, 1994)
and has since been translated to other animal models, including non-
human primates (Hermann et al., 2012): the latter demonstrated the
proof-of-principle for colonization of non-human primate SSCs after
transplantation (Schlatt et al., 1999) and successful embryo develop-
ment using transplanted SSC-derived spermatozoa (Hermann et al.,
2012). This method was reproduced and further optimised using
isolated human cadaver testes (Ning et al., 2012; Faes et al., 2013; Faes
et al., 2017). Of interest, natural conception after SSC transplantation
was successfully achieved in a mouse model and healthy offspring were
obtained for two generations, as indicated by normal general develop-
ment and absence of numerical chromosomal abnormalities or abnor-
mal epigenetic marks (Goossens et al., 2009; Goossens et al., 2010).
Because of the limited number of SSCs in biopsied prepubertal
testicular tissue, propagation of SSCs will be required for successful
clinical application of SSC auto-transplantation. Long-term propagation
of SSCs was established for the first time in 2003 in a mouse model
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Figure 2 Subclassification and proportions of cryopreserved testicular tissue samples. Data are shown for patients with malignant
diseases (n = 630; cancer treatment as indication for FP) (A), non-malignant diseases (n = 280; HSCT as indication for FP) (B) and genital, testicular
or sexual disorders (n = 105; testicular pathology or risk for it as indication for FP) (C). CNS = central nervous system; FP = fertility preservation;
HSCT = hematopoietic stem cell transplantation; NOA = non-obstructive azoospermia.
propagation in vitro, these mouse SSCs were able to colonise the
testis upon transplantation and produce differentiating germ cells,
which could be used to generate healthy offspring after round
spermatid injection and ICSI. Subsequently, in vitro SSC propagation
was achieved in various animal models including rat (Hamra et al.,
2005), bovine (Aponte et al., 2008), porcine (Zhang et al., 2017) and
tree shrew (Li et al., 2017). More importantly, for future restoration
of fertility using auto-transplantation, human SSCs from adult and




















ability to home into their niches within the seminiferous tubules of
a recipient testis has been demonstrated by xeno-transplantation
(Sadri-Ardekani et al., 2009; Sadri-Ardekani et al., 2011). Similar human
SSC propagation cultures, with minor adaptations in culture medium,
have subsequently been reported (He et al., 2010; Koruji et al.,
2012; Conrad et al., 2014; Zheng et al., 2014; Dong et al., 2019).
Although there is proof-of-principle on the ability of human SSCs
to propagate in vitro, the remaining somatic cells also propagate in
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very low percentage of SSCs. Therefore, further characterization of
human SSC culture conditions is required to improve SSC isolation
and propagation. Several specific molecular markers have been
suggested to quantify human SSCs in culture (He et al., 2010;
Kossack et al., 2013; Smith et al., 2014; Zheng et al., 2014), and
recent studies described the gene expression profile of several
spermatogonial subtypes (Guo et al., 2018; Hermann et al., 2018;
Wang et al., 2018; Sohni et al., 2019), but none of these can speci-
fically identify SSCs. SSCs can only be conclusively distinguished from
the undifferentiated spermatogonial population by their stem cell
properties of self-renewal and differentiation using the transplanta-
tion assay, where an almost linear correlation between the extent
of spermatogenesis and the number of transplanted SSCs was
demonstrated in mice (Dobrinski et al., 1999). A limited number of
papers have reported the capacity of cultured human SSCs sorted
for a selected marker to migrate to the SSC niche on the seminiferous
membrane after xeno-transplantation in the mouse testis (Langen-
stroth et al., 2014; Nickkholgh et al., 2014a). Identifying specific markers
(or a combination of markers) for SSCs will be pivotal for optimising
SSC propagation in vitro and for developing standardised protocols for
SSC transplantation therapy.
Clinical translation of SSC therapy is also dependant on the stability
and safety of propagated SSCs. Data on genetic and epigenetic
stability of SSCs during culture or upon differentiation are limited
and mainly involve animal models (Kanatsu-Shinohara et al., 2005;
Langenstroth-Rower et al., 2017). On the other hand, in several studies
it has been shown that transplantation of uncultured or cultured
SSCs did not lead to tumours in the testes of recipients 3 months
after transplantation in a mouse model or in a human-to-mouse
xeno-transplantation model (Nagano et al., 2002; Sadri-Ardekani
et al., 2009; Sadri-Ardekani et al., 2011; Nickkholgh et al., 2014b)
indicating no tumorigenic transformation of the SSCs in these studies.
Also, after transplantation of cultured SSCs in a mouse model,
no differences were observed in health effects compared to non-
transplanted control mice in terms of increased risk of tumorigenesis
and life expectancy (Mulder et al., 2018). However, more sensitive
methods are needed to address the safety aspect more in detail,
and exclude potential genetic and epigenetic changes in the cultured
cells.
A drawback of transplanting cells from a testicular biopsy is the
potential risk to reintroduce cancerous cells that have been infiltrating
the testis before biopsy. Such a risk might occur in patients with
non-solid tumours such as leukaemia or blood-metastasising tumours.
Although, several papers have reported promising results for cell
sorting of leukemic cells from testicular cell suspensions (Dovey et al.,
2013; Sadri-Ardekani et al., 2014), other studies highlight the risk of
cancer cell contamination in such testicular cell preparations (Hou et
al., 2007, 2009; Kilcoyne and Mitchell 2019). In conclusion, currently
there are no clinical methods available to exclude the possibility of
potential cancer contamination in testicular cells or tissue samples.
Therefore, these samples should not be used in clinical re-implantation
strategies.
Taken together, during the last decade progress has been made on
several aspects of a future SSC transplantation therapy to restore
fertility in childhood cancer survivors. The most critical step in this
therapy will be optimising SSC propagation in vitro to establish a safe






























































































































Transplantation of fragments of testicular tissue provides an alternative
strategy to the use of SSC suspensions. This approach maintains
the SSCs within their unexposed natural niche, thus preserving the
interactions between the germ cells and their supporting somatic
cells. Autologous transplantation of the testicular biopsy can however
only be proposed for restoring spermatogenesis if the presence of
malignant cells can be excluded (Kilcoyne and Mitchell, 2019).
Tissue can be grafted to an ectopic or homotopic location. Initially,
in mouse models, grafting was performed to ectopic sites, such as
in the peritoneal space, the ear or under the back skin (Boyle et al.,
1975; Schlatt et al., 2002). Full spermatogenesis was reported in
xenografts from several species (Honaramooz et al., 2002; Schlatt et al.,
2002; Schlatt et al., 2003; Honaramooz et al., 2004; Oatley et al., 2004;
Snedaker et al., 2004; Rathi et al., 2006; Zeng et al., 2006; Abrishami
et al., 2010; Liu et al., 2016), but never in xenografts from marmoset
(Schlatt et al., 2002; Wistuba et al., 2004) or human (Goossens et al.,
2008). The higher temperature at these ectopic sites compared with
the scrotum was suggested to be the cause of either sclerosis of the
graft or meiotic arrest. Consequently, tissue was grafted to the scro-
tum of castrated animals. Xeno-transplantation of immature human
testicular tissue to the scrotum of immunodeficient mice maintained
SSC proliferation (Wyns et al., 2007) and permitted initiation of
differentiation up to the spermatid stage on histological morphological
examination, although differentiation appeared abnormal based on
electron microscopy characteristics and immunocytochemical markers
(Wyns et al., 2008). The potential to successfully restore fertility might
be improved by transplanting human tissue under the tunica albuginea
of the testis (intratesticular grafting) as, in mice, this technique proved
highly efficient with the re-establishment of full spermatogenesis in
all of the grafts (Van Saen et al., 2009). Spermatogenesis has also
been achieved using prepubertal primate tissue xenografted into the
mouse testis. So far, the most advanced germ cell type obtained
after xenografting non-human primate immature testis tissue to mouse
testis is secondary spermatocytes specified by Boule Homolog and
phosphorylated H2A histone family member X expression (Ntemou
et al., 2019b).
Compared with ectopic xenografting, xenotransplantation of
prepubertal human testis tissue into the mouse testis also resulted in
better graft survival and initiation of germ cell differentiation (Van Saen
et al., 2011). Although meiosis could be observed after intratesticular
grafting of human testis tissue into the mouse, a considerable loss
of SSCs was reported. This loss resulted from degeneration of
tubules in the centre of the graft, possibly due to hypoxia during
the first days after grafting (Van Saen et al., 2013). To reduce this SSC
loss, early blood supply to the grafted tissue should be stimulated.
Vascular endothelial growth factor (VEGF) is an important regulator
of angiogenesis during development as well as in adulthood (Holmes
and Zachary, 2005). In bovine, VEGF-treated grafts showed increased
graft weight and more tubules contained elongating spermatids. These
VEGF-treated grafts tended to have a better vasculature compared
with control grafts (Schmidt et al., 2006). In addition to its role in
angiogenesis, VEGF also regulates SSC homeostasis (Caires et al.,
2012). In vitro treatment with VEGF prior to grafting prevented germ
cell death and stimulated differentiation in bovine grafts (Caires et al.,
2009). When immature human testicular tissue was embedded in
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the mouse scrotum, revascularisation and spermatogonial survival
improved (Poels et al., 2016). This was also the case when immature
human testicular tissue was pretreated with VEGF in vitro before
intratesticular xenotransplantation. However, VEGF did not influence
germ cell differentiation (Ntemou et al., 2019a).
Autologous transplantation has been performed in non-human pri-
mates. When testicular fragments were grafted under the skin of
adult marmosets or rhesus macaques, meiotic arrest was observed in
the grafts (Luetjens et al., 2008; Jahnukainen et al., 2012). However,
fragments grafted to the scrotum re-established full spermatogenesis,
although spermatogenic efficiency remained poor (Luetjens et al.,
2008, Jahnukainen et al., 2012). In 2016, healthy monkeys were born
after ICSI using sperm from ectopic xenografts (Liu et al., 2016). In
2019, transplantation of macaque testicular fragments to castrated
immature macaques (under the skin and in the scrotum) showed
very high efficiency of fertility restoration, with the birth of a healthy
female baby after ICSI (Fayomi et al., 2019). Neither the addition
of Matrigel nor cryopreservation nor graft location had an impact
on the percentage of tubules displaying complete spermatogenesis.
Interestingly, compared to other studies, in this study, unusually large
fragments were transplanted (9–20 mm3).
Ectopic or scrotal grafting always has to be combined with ICSI in
order to generate offspring. Also, for intratesticular grafts, it is still
an open question whether connections can be established between
grafted and endogenous tubules, ensuring a functional excretory sys-
tem. However, grafting studies in rodent models have never reported
the presence of donor-derived spermatozoa in the epididymis and,
thus, the chance for natural reproduction may be very small. Due to
the lack of an excretory system in case of the intratesticular/scrotal
grafts, spermatozoa and fluid may accumulate and cause damage to the
testis epithelium (Pilsworth et al., 1981). Therefore, spermatogenesis
in grafts may not occur indefinitely.
In vitro differentiation of male germ cells
obtained before and after puberty
Until robust decontamination protocols have been established, options
to restore fertility in patients with malignant haematological diseases
are limited to strategies enabling the isolation and cryopreservation of
sperm generated in vitro.
Studies in the late 1990s revealed a potential use of in vitro generated
sperm for fertility restoration in adult azoospermic patients. In these
studies, the in vitro differentiation of primary spermatocytes into hap-
loid cells could be observed after 48 h of culture (Tesarik et al., 1999).
Subsequently, these haploid cells were reported to be functional,
resulting in the birth of healthy babies after ICSI (Tesarik et al., 1999).
Later studies performed by other research groups revealed similar
results in terms of germ cell differentiation. In a study published in 2003,
co-cultures with Vero cells allowed the division of spermatocytes into
four cells, identified as haploid spermatids (Tanaka et al., 2003).
In 2014, functional haploid spermatids were generated by culturing
SSCs from adult patients with cryptorchidism in conventional con-
ditions (DMEM/F12 medium supplemented with 10% foetal bovine
serum, retinoic acid and stem cell factor) for 7 to 10 days. The
functionality of these in vitro generated haploid cells was tested by
injecting them into murine oocytes, resulting in the production of eight-





























































































































The combination of functional somatic cells in direct contact with
germ cells cultured in vitro has been reported by several groups to be
an important factor to ensure survival and differentiation of male germ
cells (for review, see Alves-Lopes and Stukenborg, 2017). In addition
to the direct contact of different cell populations, the importance
of a functional microenvironment resembling the 3D organization of
the seminiferous epithelium in situ has been highlighted in several
studies. Three-dimensional conditions, such as explant testicular tissue
cultures or testicular organoids, are today the most promising strate-
gies for establishing a functional in vitro tool for fertility preservation
(Alves-Lopes and Stukenborg 2017; Oliver and Stukenborg 2019).
Historically, the first organotypic culture of testicular tissue from
prepubertal rats was performed in 1964. The testicular fragments
were deposited on a thin layer of agarose positioned on a metal
grid allowing simultaneous contact between the culture medium and
the air (Steinberger et al., 1964). This method resulted in meiotic
entry and appearance of pachytene spermatocytes in testicular tis-
sue from 12-day-old rats after 2 to 3 weeks of culture (Steinberger
and Steinberger, 1965). The organotypic culture system then evolved
by removing the metal grid and replacing it with a semi-permeable
membrane. This new model has made it possible to maintain tissue
architecture over short periods of culture. Organotypic culture using
this membrane system allowed the evaluation of freezing protocols
for prepubertal mouse testicular tissue. This work has shown the
growth of seminiferous tubules, the maintenance of intra-tubular cell
proliferation and the initiation of meiosis up to zygotene spermatocytes
(Milazzo et al., 2008). In humans, the culture of prepubertal testicular
tissue has allowed the survival of spermatogonia and the maintenance
of seminiferous tubule architecture (Kvist et al., 2006; Keros et al.,
2007). However, semi-permeable membrane culture did not produce
complete spermatogenesis.
In 2010, the use of agarose blocks on which the testicular frag-
ments are deposited combined with a modification of the culture
medium allowed the progression of spermatogenesis up to round
spermatids from prepubertal mouse testicular tissue (Gohbara et al.,
2010). Complete spermatogenesis was reported in fresh prepubertal
mouse testicular tissue by replacing foetal bovine serum with Knockout
Serum Replacement. Viable and fertile progeny were subsequently
obtained after ICSI (Sato et al., 2011). Similar results have been
reported after culture of prepubertal mouse testicular tissue previously
frozen by uncontrolled slow freezing or vitrification (Yokonishi et al.,
2014). The yield of in vitro spermatogenesis has been enhanced after
culture of fresh or frozen prepubertal mouse testicular tissue with
retinol in the culture medium (Arkoun et al., 2015). More recently, a
microfluidic culture system that allows the culture of testicular tissue in
monolayer for more than 6 months with continuous circulation of the
culture medium significantly increased the production of post-meiotic
cells from fresh prepubertal mouse testicular tissue (Komeya et al.,
2017). To date, the mouse is the only species in which complete sper-
matogenesis has been obtained from testicular fragments resulting in
functional sperm. However, one study reported complete meiosis after
culture on agarose gel of fresh rat prepubertal testicular tissue, without
reaching elongated sperm production (Reda et al., 2016). In the same
year, culture of seminiferous tubules using chitosan produced haploid
cells from prepubertal rat testicular tissue and human testicular tissue
from adult males treated with oestrogen within the context of gender
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Table II Current challenges in the field of male fertility preservation.
.......................................................................................................................................................................................
Clinical challenges
1. Optimization of patient inclusion and exclusion criteria
2. Standardization of protocols for the collection and cryopreservation of testicular tissue
3. Optimization of protocols for the management and transportation of tissue between the procurement site and cryopreservation site
4. Development of protocols for quality assurance before and after storage
5. Development of protocols for minimal residual disease testing of testicular tissue
6. Development of protocols for follow-up of patients after testicular biopsy
Research challenges
1. Development of protocols for cell sorting to isolate spermatogonial stem cells (SSCs) and/or exclude cancer cells
2. Optimization of protocols for propagation of SSCs
3. Obtaining proof-of-concept of auto-transplantation methodologies for testicular tissue and SSCs in human
4. Development of protocols for IVM of human SSCs
5. Evaluation of the genetic and epigenetic stability and hence safety of cryopreserved, cultured and transplanted human SSCs and in vitro-derived sperm
6. Assessment of the fertilising capacity of sperm obtained after fertility restoration
tubules as early as 34 days of culture instead of the usual 72 days in
physiological conditions (Perrard et al., 2016). More recently, meiotic
(Medrano et al., 2018) and post-meiotic (Abofoul-Azab et al., 2018)
cells have also been obtained from children aged 7 to 14 years, after
organotypic culture of testicular tissues or 3D-culture conditions using
dissociated cells, respectively. In addition, a study using frozen testicular
tissue from young boys aged 2 to 12 years revealed the production
of haploid cells after organotypic culture (de Michele et al., 2018b).
However, to date, no studies have reported the in vitro production of
spermatozoa from human prepubertal testicular tissue. Studies on the
molecular mechanisms during organotypic culture that could explain
the absence of spermiogenesis showed incomplete establishment of
the blood-testis barrier (de Michele et al., 2018a).
The lack of a reliable functional approach and experimental condi-
tions that mimic specific endocrine and paracrine pathways needed for
male germ cell differentiation highlight the need for more research to
establish robust in vitro conditions for fertility preservation in males.
Ethical Issues of Testicular
Tissue Cryopreservation
The main ethical issue regarding fertility preservation in prepubertal
boys remains the experimental nature of the intervention. Clinical
research involving children is subject to a strict balance between
burdens and risks on the one hand and the anticipated benefit for the
child on the other hand (Lee, 2018). Given the fact that efficacy of
the subsequent clinical applications has not been proven, it is crucial
to offer the procedure only if the risks and burdens for the child are
kept to a minimum. Thus, contrary to the situation for postpubertal
patients where cryopreservation of sperm should be proposed, offer-
ing testicular tissue cryopreservation in prepubertal boys is ethically
permissible in some cases but is not ethically required (McDougall
et al., 2018). Some authors suggest that testicular tissue cryopreser-
vation should not be restricted to the experimental setting (Ruutiainen















































































technologies without the necessary safeguards, it seems premature
to move testicular tissue cryopreservation out of the experimental
setting because of possible negative effects on patients (including the
parents) and because all three steps of the technology (collection, cry-
opreservation and re-transplantation) do not fulfil the basic criteria to
be considered as innovative treatment: no proof-of-principle in humans
and, as a consequence, no data on safety, procedure and effectiveness
(Provoost et al., 2014). The proposal to allow the application outside
the experimental setting was meant to increase access. However,
problems of access can be solved in other ways than by changing the
scientific status (Mertes and Pennings, 2013).
The benefit of the technology is determined by the importance
attributed to genetic parenthood and by the belief in scientific progress.
Parents’ beliefs in scientific progress that will enable the use of the
stored material influences their willingness to have their child undergo
the tissue collection (Ginsberg et al., 2014). This belief changes the
assumed balance of harms and benefits. Still, one may wonder when
belief in scientific progress turns into therapeutic misconception or
false hope. Moreover, as soon as some degree of scientific progress is
envisioned, other alternative developments should also be considered.
Stem cell-derived gametes, from induced pluripotent stem cells for
instance, may be a possibility in the future, thus making the surgical
intervention to harvest testicular tissue redundant (Hayashi et al.,
2011). However, today there is no robust protocol available allowing
the differentiation of human pluripotent stem cells into functional
germ cells.
The main justification for offering fertility preservation is the possi-
bility to preserve the ability to have genetically related children. The
importance of this possibility is corroborated by studies indicating the
importance of fertility in (surviving) cancer patients. However, another
indicator of the importance could be the utilization rate of the stored
material. While the majority of the cancer patients indicate that having
genetically related children is important, the present utilization rate of
frozen sperm in cancer patient populations is very low (Ferrari et al.,
2016). The general investment needed for re-transplantation makes it






/hropen/article-abstract/2020/3/hoaa016/5848713 by guest on 09 June 2020
An update on fertility preservation in boys 13
after testicular tissue cryopreservation. Follow-up research on future
use is necessary for the ethical evaluation.
The Next Challenges
Since testicular tissue grafting is a relatively easy technique and has
been proven successful in primates, the next step is to obtain proof-
of-concept in humans. Some experts in the field have recommended
transplanting multiple tissue fragments to different sites on the body in
order to have a realistic chance of retrieving spermatozoa. However,
it should be noted that testicular tissue grafting would include a second
surgery to retrieve spermatozoa to be used in ART.
For patients at risk of testicular tissue contamination by cancer cells,
effective strategies to ensure the removal of malignant cells from the
tissues need further study. As the efficiency of SSC transplantation is
rather low in mice and because biopsies taken from prepubertal boys
are small and contain few SSCs, the SSCs should be propagated in vitro
prior to transplantation to increase the chance of fertility restoration.
However, in vitro culture systems need further optimization concerning
efficiency and safety before they are suitable for clinical application.
As an alternative approach to transplantation, in vitro spermato-
genesis using patient tissue may be a future option; however, this
methodology requires extensive further research before it could be
suitable for clinical application (Table II).
Conclusion
Worldwide, fertility preservation is increasingly being offered to pre-
pubertal male patients who are at risk of germ cell loss. Since the first
survey in 2012, the number of patients with stored testicular tissue
has increased from 266 to 1033. At the same time, important scientific
progress has been made concerning fertility restoration methods.
The technique of SSC transplantation has been translated to human
cadaver testis, proof-of-concept has been obtained for testicular tissue
grafting in non-human primates, and important steps have been taken
in establishing spermatogenesis in vitro.
Considering the progress that has been made and the barriers that
still have to be overcome, the first patients eligible for autologous
transplantation of testicular tissue or cell suspensions are likely to
be those treated for solid non-metastatic tumours or non-malignant
diseases, as for these patients there is no known risk of re-introducing
malignant cells into the testis. However, until successful clinical trials
demonstrating safety and efficacy of fertility restoration have been
conducted, testicular tissue cryopreservation for fertility preservation
should remain experimental.
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